Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chaperone Technologies Inc.

Latest From Chaperone Technologies Inc.

Scrip Asia 100 - Influential Asia-Pacific pharma and biotech players

Company Country - HQ Principal officer - Role Focus/ area of specialty News flow Financial performance (FY 2009) ADImmune Taiwan - Taipei Ignatius Wei - President vaccine development and commer- cialisation n/a private company AnGes MG Japan - Osaka Ei Yamada - President and CEO drug development AnGes MG is granted a patent in Japan for a new decoy oligonucleotide (2009) total revenue: Yen585 million aRigen Japan - Tokyo Gensuke Tokoro - President and CEO drug discovery and development aRigen and CJ CheilJedang sign an agreement to jointly develop ARH-1029 for the treatment of peptic ulcer disease (2010) private company Astellas Japan - Tokyo Masafumi Nogimori - President and CEO drug development and commer- cialisation Astellas completes $ 4 billion acquisition of OSI Pharmaceuticals (2010) net sales: Yen974.88 billion Crystal Genomics South Korea - Seoul Dr Cho Joong Myung* - President and CEO drug discovery and development CrystalGenomics to merge with BexPharm, a South Korean speciality pharmaceutical company (2010) private company Daiichi Sankyo Japan - Tokyo Takashi Shoda - President and CEO drug development and commer- cialisation Daiichi Sankyo launches Rezaltas combination tablets for the treatment of hypertension in Japan (2010) net sales: Yen952.1 billion Eisai Japan - Tokyo Haruo Naito - President and CEO drug development and commer- cialisation Eisai establishes new sales subsidiary in Canada (2010) net sales: Yen803 billion Fujifilm Japan - Tokyo Shigetaka Komori - President and CEO divisions for medical imaging and diagnostics Fujifilm’s subsidiaries, Perseus Proteomics and Fujifilm RI Pharma, present the development of a new radiolabelled anticancer antibody to a meeting of the Society of Nuclear Medicine (2010) revenue: Yen2,434 billion Histostem South Korea - Seoul Dr Hoon Han - President biotechnology n/a private company Hutchison Medipharma ** China - Shanghai Dr Samantha Du - CEO drug discovery and development signs agreement with Ortho-McNeil-Janssen Pharmaceuticals to discover and develop therapeutics to treat inflammatory and immune diseases (2008) sales: $111 million (parent company) HUYA Bioscience China - Shanghai and San Diego, US Dr Mireille Gingras - CEO biopharmaceutical development Huya announces a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (2010) private company Indofarma Indonesia - Jakarta P Sudibyo - Managing director drug development and commer- cialisation Indofarma and 3M Indonesia sign a partnership to market, distribute and sell 3M’s nitroglycerin transdermal patch system (2010) private company Innova Biotech Thailand - Bangkok n/a - n/a immuno- diagnostics n/a private company Kalbe Farma Indonesia - Jakarta Johannes Setijono - President and director drug development and commer- cialisation n/a sales: Rupiah9,087 billion LG Life Sciences South Korea - Seoul Kim In-Chull* - President and CEO drug development and commer- cialisation LG Life Sciences announces the discovery of new necrosis inhibitors (2009) sales: Won327.3 billion Macrogen South Korea - Seoul Seo Jeongsun - Chairman biotechnology Macrogen research team publishes a genome map of a Korean male in the journal Nature (2009) sales: Won22.46 billion Medigen Biotechnology Taiwan - Taipei Dr Stanley Chang* - Chairman and CEO drug development and diagnostics Medigen receives ASHI laboratory accreditation for HLA typing (2009) n/a Medipost South Korea - Yongin-si Jin Chang-Hyun - CEO biotechnology n/a n/a MerLion Pharma Singapore - Singapore Dr Tony Buss - President and CEO contract research and drug development MerLion and Chaperone Technologies collaborate on the development of new antimicrobials (2009) private company MicuRx/ Cumencor Pharma (MicuRx’s Chinese affiliate) China - Shanghai and Hayward, CA, US Dr Yuan Zhengyu - President and CEO drug discovery and development MicuRx and Cumenor Pharmaceuticals partner with Pfizer to discover and develop antibiotics for drug-resistant TB in China (2010); MicuRx raises $10 million in a series A financing round (2007) private company Moleac Singapore - Singapore David Picard - CEO drug development and commer- cialisation opens office in Paris, France (2009); launches NeuroAiD in Iran, Jordan, Pakistan and Thailand (2009) private company RNL Bio South Korea - Seoul Dr Ra Jeong-Chan - President biotechnology RNL Bio and Start Licensing settle patent disputes and conclude a licence agreement on animal cloning (2010) private company S*BIO Singapore - Singapore Dr Jan-Anders Karlsson*** - CEO drug development S*Bio presents positive safety and tolerability results for its novel oral JAK2 inhibitor SB1518 from a Phase I/II study for the treatment of myelofibrosis (2010) private company Shenzhen SiBiono GeneTech China - Shenzhen Dr Peng Zhaohin - Chairman and CEO gene therapy n/a n/a Shionogi Japan - Osaka Dr Isao Teshirogi - President drug development and commer- cialisation Shionogi announces the establishment of a new Japanese research subsidiary, Shionogi Techno Advance Research (2010) net sales: Yen227.5 billion Sinovac Biotech China - Beijing Dr Yin Weidong* - President and CEO vaccine development and commer- cialisation Sinovac completes $17.6 million buildings and land acquisition to expand vaccine production capacity (2010) sales: $84.20 million TaiGen Biotech Taiwan - Taipei Dr Hsu Ming-Chu* - Chairman, president and CEO drug discovery TaiGen raises $37 million in a series C financing round (2009) private company TaiMed Biologics Taiwan - Taipei James Chang - CEO drug development n/a private company Taiwan Biotech Taiwan - Taoyuan City n/a - n/a drug development and commer- cialisation n/a private company Takara Bio Japan - Shiga Koichi Nakao - President and CEO biotechnology Takara Bio executes a collaborative research agreement with the University of Pennsylvania to support an HIV gene therapy clinical trial in the US (2010) net sales: Yen18,913 million Takeda Japan - Osaka Yasuchika Hasegawa - President drug development and commercialisation Takeda plans to establish a new commercial subsidiary in South Korea (2010) sales: Yen1,466 billion UMN Pharma Japan - Akita City Dr Shu-Ichi Kanazashi - President and CEO drug development and commer- cialisation UMN Pharma and API Co announce formulation process collaboration for influenza vaccine candidate UMN-0501 (2010) private company United Laboratories (Unilab) Philippines - Mandaluyong City Jocelyn Campos-Hess - Chairperson drug development and commer- cialisation n/a private company Viromed South Korea - Seoul Dr Kim Sunyoung and Kim Yongsoo - Co-CEOs drug development Viromed completes merger with Helixir Co, a developer of phytotherapeutics (2009) revenues: $7.66 million

*Scrip Asia 100 ’Shining Star’; **Hutchinson China MediTech, part of Chi-Med; ***interviewed in Scrip Asia 100

Source: Scrip analysis

Cardiovascular Dermatology

Start-Up Previews (6/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Filling in the Gaps in AAA Repair, features CardioMEMS Inc., EVA Corp. and Medical Metrx Solutions Inc.. Plus these Start-Ups across Health Care: BioRexis Pharmaceutical Corp., Calypso Medical Technologies Inc., Chaperone Technologies Inc., QRxPharma Pty. Ltd. and Sequential Inc.

Chaperone Technologies Inc.

More than 70% of the bacteria that cause hospital-acquired infections are resistant to at least one of the broad-spectrum antibiotics most commonly used to treat them. By targeting peptides at a single vital intracellular structure found in all microbes, Chaperone Technologies hopes to solve the drug resistance problem for good.

Selected Start-Ups (9/03)

In Vivo briefly summarizes the technologies of these recently founded companies: AnalgesiX Inc., Chaperone Technologies Inc., Chlorogen Inc., GI Dynamics Inc., Kinexis Inc. and PharmaEngine Inc.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals